This Ketoacidosis Side Effect For These New Diabetes Medicines Was The Subject Of A May 2015 FDA Drug Safety Warning Which Was, Perhaps, Not Strong Enough About Dangers
SUMMARY: At the June 2015 American Diabetes Association 2015 Scientific Sessions in Boston the findings of a new medical study about the significance of repeat incidents of diabetic ketoacidosis (DKA) as regards mortality rate were presented in this Abstract: “273-OR – Previous Diabetic Ketoacidosis Is Associated with a Significant Risk of Death in the following 5 Years”.
In this article, “May 2015 Diabetes Drugs – Ketoacidosis Link Warning By FDA Covers Invokana, Farxiga, And Jardiance, With Label Changes Possible”, we reported about the recent “FDA Drug Safety Communication: FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood”, issued on May 15, 2012.
This SGLT2 inhibitors class of drugs consists of:
Invokana — FDA Approval: 2013
Invokamet — FDA Approval: 2014
Farxiga — FDA Approval: 2014
Xigduo XR — FDA Approval: 2014
Jardiance — FDA Approval: 2014
Glyxambi — FDA Approval: 2015
We are currently investigating possible drug injury lawsuits against the responsible pharmaceutical companies for diabetes patients who have developed ketoacidosis as well as certain other “side-effect” medical conditions such as kidney problems, heart attacks, and strokes.[Read this article in full at original source]
Invokana / Farxiga / Jardiance
Free Case Evaluation
Strictly Confidential, No Obligation.